Atypical Locations of Renal Cell Carcinoma Metastases to the Pancreas and Duodenum

Piskorz, Łukasz; Mitura, Kryspin; Olejniczak, Witold; Misiak, Piotr; Jabłoński, Sławomir

doi:10.2147/rru.s290150

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Piskorz et al reported their experience in a similar case of RCC invading the pancreas and confirmed better survival with surgical excision. Their patient had 2 years follow-up showing no evidence of recurrence (19). Gonzalez et al reported their experience on doing extensive surgeries of 18 patients having RCC invading liver, spleen and/or the duodenum.…”

Section: Discussionmentioning

confidence: 99%

Successful Surgical Management of Locally Advanced Renal Cell Carcinoma Invading Spleen and Pancreas

Sharafeldeen

Mehrnoush

Ismail

et al. 2022

jkcvhl

View full text Add to dashboard Cite

Over the last two decades, the treatment of metastatic RCC has changed significantly, and the role of surgery is being debated. A 50-year-old man presented with pain in his left loin. An ultrasound, followed by a CT scan, revealed a 17.5 cm left renal mass invading the left suprarenal gland, spleen, and pancreatic tail. Radical nephrectomy through chevron incision under epidural block with general anesthesia was performed. The entire mass was removed en bloc. The estimated blood loss was 300 mL, and no blood transfusions were performed. The operation took approximately 2 h. Histological examination revealed clear cell renal carcinoma with extension into the spleen, pancreatic tail, and diaphragmatic fibers with negative resection margin. The patient discharged after a 3-day uneventful hospital stay. Aggressive surgical removal of a locally invasive renal cell carcinoma is feasible and should be considered in patients with good performance status and no or minimal distant metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Surgical Management of Locally Advanced Renal Cell Carcinoma Invading Spleen and Pancreas

Sharafeldeen

Mehrnoush

Ismail

et al. 2022

jkcvhl

View full text Add to dashboard Cite

show abstract

“…Moreover, as reported in one of our cases, digestive involvement of RCC metastasis includes gastrointestinal tract (stomach, duodenum, colon), ampulla of Vater and gallbladder in addition to the pancreas. Metastases can occur simultaneously in GI sites, as in our case, or at different timepoints during follow-up [ 20 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 ].…”

Section: Discussionmentioning

confidence: 99%

Metastatic Renal Cell Carcinoma to Pancreas: Case Series and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Metastasis to the pancreas represents a small proportion of all pancreatic malignancies. Among primary tumors that metastasize to the pancreas, renal cell carcinoma (RCC) is one of the most common causes of metastatic pancreatic lesions. We herein report a case series of three patients with pancreatic metastasis from RCC. The first is a 54-year-old male with a history of left nephrectomy for RCC, in whom an isthmic pancreatic mass suggestive of a neuroendocrine lesion was found during oncological follow-up. Endoscopic ultrasound (EUS)-guided fine needle biopsy (FNB) identified pancreatic metastasis of RCC and the patient was referred for surgery. The second case is a 61-year-old male, hypertensive, diabetic, with left nephrectomy for RCC six years previously, who complained of weight loss and was found with a hyperenhancing mass in the head of the pancreas and a lesion with a similar pattern in the gallbladder. EUS-FNB from the pancreas proved to be a metastatic pancreatic lesion. Cholecystectomy and treatment with tyrosine kinase inhibitors were recommended. The third case is a 68-year-old dialysis patient referred for evaluation of a pancreatic mass, also confirmed by EUS-FNB, who was started on sunitinib treatment. We report a literature summary on epidemiology and clinical features, diagnosis and differential diagnosis and treatment and outcomes in pancreatic metastasis of RCC.

show abstract

Isolated Pancreatic Metastases of Renal Cell Cancer: Genetics and Epigenetics of an Unusual Tumour Entity

Sellner

Thalhammer

Klimpfinger

2022

Cancers

View full text Add to dashboard Cite

Isolated pancreatic metastases of renal cell carcinoma (isPMRCC) are a rare manifestation of metastatic renal cell carcinoma (mRCC) characterized by two peculiarities: (1). The definite or at least long-term exclusive occurrence of metastases in the pancreas and (2). an unusual low tumour aggressiveness with slow tumour progression and consecutive, good treatment results. According to current knowledge, the exclusive occurrence of pancreatic metastases is due to a highly specific and highly selective seed and soil mechanism, which does not allow metastases settlement outside the pancreas, and whose detailed genetic/epigenetic causes are not yet elucidated. Recent studies have shed light on some of the pathways involved for the protracted course of the disease and highlighted a special genetic profile (lack of loss of 9p, lower weight genome instability index, low frequency of BAP1 alterations, and a high frequency of PBRM1 loss), which deviates from the conventional mRCC profile. Finally, the question of the reasons for the long-term relative genetic stability of the involved cell clones, which is an essential prerequisite for a favourable prognosis, remains unanswered.

show abstract

Atypical Locations of Renal Cell Carcinoma Metastases to the Pancreas and Duodenum

Cited by 4 publications

References 22 publications

Successful Surgical Management of Locally Advanced Renal Cell Carcinoma Invading Spleen and Pancreas

Successful Surgical Management of Locally Advanced Renal Cell Carcinoma Invading Spleen and Pancreas

Metastatic Renal Cell Carcinoma to Pancreas: Case Series and Review of the Literature

Isolated Pancreatic Metastases of Renal Cell Cancer: Genetics and Epigenetics of an Unusual Tumour Entity

Contact Info

Product

Resources

About